Updates are available Correction dated 2024-08-08
Click to view Correction: https://doi.org/10.1038/s41540-024-00416-7
-
Authors
Papp, Orsolya
Jordán, Viktória
Hetey, Szabolcs
Balázs, Róbert
Kaszás, Valér
Bartha, Árpád
Ordasi, Nóra N.
Kamp, Sebestyén https://orcid.org/0000-0002-8485-6054
Farkas, Bálint https://orcid.org/0009-0005-5645-4612
Mettetal, Jerome
Dry, Jonathan R. https://orcid.org/0000-0002-1640-2616
Young, Duncan
Sidders, Ben
Bulusu, Krishna C. https://orcid.org/0000-0002-5092-6640
Veres, Daniel V. https://orcid.org/0000-0002-2968-0666
- License Information
-
More Information
Article History
Received: 22 August 2022
Accepted: 14 June 2024
First Online: 21 June 2024
Change Date: 8 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41540-024-00416-7
Competing interests
: The Authors declare no Competing Non-Financial Interests but the following Competing Financial Interests:OP, BF, and VK are full-time employees of Turbine. ÁB, RB, SK, SZH, NNO, and VJ were full-time employees for the full course of this study. DVV is a full-time employee and shareholder of Turbine. The use of Turbine’s Simulated Cell technology and the proprietary intellectual property of the platform was imperative for this study; findings are hypotheses to be confirmed through real-life validation. BS, DY, KCB, and JM are full-time employees and shareholders of AstraZeneca. JRD was employed by AstraZeneca for the full course of this study. JRD is currently an employee of Tempus, but all analysis included in this study was performed while he was employed at AstraZeneca.
: As the work was completely limited to the use of cancer cell line-derived information, which was already published, and all the novel data and insights were generated computationally, ethical approval was not required to carry out the study.
